CL2023000693A1 - Formas cristalinas de un inhibidor de kras g12c - Google Patents
Formas cristalinas de un inhibidor de kras g12cInfo
- Publication number
- CL2023000693A1 CL2023000693A1 CL2023000693A CL2023000693A CL2023000693A1 CL 2023000693 A1 CL2023000693 A1 CL 2023000693A1 CL 2023000693 A CL2023000693 A CL 2023000693A CL 2023000693 A CL2023000693 A CL 2023000693A CL 2023000693 A1 CL2023000693 A1 CL 2023000693A1
- Authority
- CL
- Chile
- Prior art keywords
- crystalline forms
- kras
- inhibitor
- relates
- present
- Prior art date
Links
- 229940125399 kras g12c inhibitor Drugs 0.000 title abstract 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
La presente invención se relaciona con formas cristalinas de un inhibidor de KRas G12C y sal de este. En particular, la presente invención se relaciona con formas cristalinas del inhibidor KRas GT2C 2-[(2S)-4-[7-(8-cloro-1-naftil)-2-[[(2S)-1-metilpirrolidin-2-il]metoxi]-6,8-dihidro-5H-pirido[3,4-d]pirimidin-4-il]-1-(2-fluoroprop-2-enoil)piperazin-2-il]acetonitrilo,composiciones farmacéuticas que comprenden las formas cristalinas, procesos para preparar las formas cristalinas y métodos de uso de estos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077553P | 2020-09-11 | 2020-09-11 | |
| US202063093673P | 2020-10-19 | 2020-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000693A1 true CL2023000693A1 (es) | 2023-10-20 |
Family
ID=80629890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000693A CL2023000693A1 (es) | 2020-09-11 | 2023-03-10 | Formas cristalinas de un inhibidor de kras g12c |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230357231A1 (es) |
| EP (1) | EP4210833A1 (es) |
| JP (1) | JP2023540809A (es) |
| KR (1) | KR20230137286A (es) |
| AU (1) | AU2021340716A1 (es) |
| BR (1) | BR112023004569A2 (es) |
| CA (1) | CA3190944A1 (es) |
| CL (1) | CL2023000693A1 (es) |
| CO (1) | CO2023004141A2 (es) |
| IL (1) | IL301236A (es) |
| MX (1) | MX2023002942A (es) |
| WO (1) | WO2022056307A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| KR20240004960A (ko) | 2021-05-05 | 2024-01-11 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10647715B2 (en) * | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| WO2019099524A1 (en) * | 2017-11-15 | 2019-05-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| MX2022003537A (es) * | 2019-09-24 | 2022-07-11 | Mirati Therapeutics Inc | Terapias de combinacion. |
-
2021
- 2021-09-10 EP EP21867707.8A patent/EP4210833A1/en active Pending
- 2021-09-10 MX MX2023002942A patent/MX2023002942A/es unknown
- 2021-09-10 WO PCT/US2021/049940 patent/WO2022056307A1/en active Application Filing
- 2021-09-10 AU AU2021340716A patent/AU2021340716A1/en active Pending
- 2021-09-10 US US18/025,817 patent/US20230357231A1/en active Pending
- 2021-09-10 CA CA3190944A patent/CA3190944A1/en active Pending
- 2021-09-10 JP JP2023516126A patent/JP2023540809A/ja active Pending
- 2021-09-10 IL IL301236A patent/IL301236A/en unknown
- 2021-09-10 KR KR1020237012251A patent/KR20230137286A/ko unknown
- 2021-09-10 BR BR112023004569A patent/BR112023004569A2/pt unknown
-
2023
- 2023-03-10 CL CL2023000693A patent/CL2023000693A1/es unknown
- 2023-03-30 CO CONC2023/0004141A patent/CO2023004141A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023540809A (ja) | 2023-09-26 |
| US20230357231A1 (en) | 2023-11-09 |
| AU2021340716A1 (en) | 2023-03-30 |
| IL301236A (en) | 2023-05-01 |
| KR20230137286A (ko) | 2023-10-04 |
| CA3190944A1 (en) | 2022-03-17 |
| WO2022056307A1 (en) | 2022-03-17 |
| CO2023004141A2 (es) | 2023-08-28 |
| EP4210833A1 (en) | 2023-07-19 |
| BR112023004569A2 (pt) | 2023-04-04 |
| MX2023002942A (es) | 2023-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000693A1 (es) | Formas cristalinas de un inhibidor de kras g12c | |
| UY28946A1 (es) | Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios | |
| ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
| AR051735A1 (es) | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| UY28059A1 (es) | Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos. | |
| CO6331437A2 (es) | Compuestos de pirrolo[2,3-d]pirimidina | |
| PA8601701A1 (es) | Compuestos farmacéuticos novedosos | |
| ECSP066763A (es) | Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes | |
| ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
| PE20080263A1 (es) | Compuestos de pirrolo-pirimidina y sus usos | |
| AR047917A1 (es) | Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos | |
| CY1106788T1 (el) | Πυριμιδινες και τριαζινες αναστολης της αντιγραφης του hiv | |
| AR058780A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| UY32156A (es) | Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones. | |
| AR033678A1 (es) | Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados | |
| HN2010000653A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b | |
| ECSP088345A (es) | Nuevas pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina | |
| CO6150138A2 (es) | Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc | |
| PA8617701A1 (es) | Nuevos compuestos farmaceuticos | |
| CY1122514T1 (el) | Σουλφονικος υδροξυαιθυλεστερας του αναστολεα της εξαρτωμενης απο κυκλινη πρωτεϊνικης κινασης, κρυσταλλικη μορφη αυτου και μεθοδος παρασκευης αυτου | |
| PE20150637A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| UY29233A1 (es) | Procedimiento para preparar derivados condensados de piperazin-2-ona | |
| CR11433A (es) | Inhibidores de quinasa c-fms | |
| UY30298A1 (es) | Inhibidores de la quinasa c-fms ii |